Navigation Links
US Oncology Provides Full Service Management of Clinical Trials
Date:4/2/2009

HOUSTON, April 2 /PRNewswire/ -- US Oncology, the nation's foremost cancer treatment and research network, has established US Oncology Clinical Development (USOCD), a full service contract research organization (CRO).

USOCD formalizes many of the services that US Oncology Research has provided since its inception in 1999. For more than a decade US Oncology Research has offered pharmaceutical and biotechnology companies elements of the clinical trial management process. The formation of USOCD focuses the company's extensive resources in order to provide full service CRO capabilities with expertise in the following areas:

  • Phase I Clinical Trials (inpatient and outpatient, including First in Man)
  • Phase II-IV Clinical Trials
  • Physician Advisory Boards
  • Safety Data Collection and Regulatory Submission
  • Data Management (Registration Desk)
  • Biostatistics
  • Medical Writing and Protocol Development
  • Medical Monitoring
  • Regulatory Document Collection and Submissions
  • Monitoring & Auditing
  • Site Selection and Payments
  • Central IRB
  • True Feasibility Data


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...IN, Calif., Dec. 2 Pereg...reported completion of patient enrollment in a dos... in patients with relapsed glioblastoma multiforme...a is a targeted monoclonal antibody linked to a ra...tment for GBM. Cotara specifically targets cells ...
(Date:12/2/2009)... JERUSALEM, Israel, December 2 ...aluating the preclinical (animal study) safety and... technology from Weill,Cornell Medical College and...eat inherited anemias such as Cooley,s Anemia. ,...nologies to expand, ex vivo,populations of stem/p...
(Date:12/2/2009)...SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is... turmoil and uncertainty is part of many,businesse...ustry has been,relatively immune to the economic d..., During the midst of the difficult times... Johnson inaugurated an R&D center in Shanghai...
(Date:12/1/2009)...EW YORK, Dec. 1 Reportlinker.com a...lable in its catalogue: ,, Chromium - Global .../p0164494/Chromium---Global-Market-Trends.html ,...luenced by stainless steel, while growth in aerosp...ortant for growth of chromium metal. Environmental...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9
...olved; Remaining Issues Pertain to cGMP Co...ompany Expects to Resolve cGMP Issues in the Next ...s,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today ann...r from the U.S. Food and Drug Administration (FDA)...turing and controls (CMC) NDA,supplement submitted...
...st, the leader in,at-home diagnostic sleep testing...f an improved version of its main web site,( http:...its community of,patients, family members, and hea...or in-home sleep testing and sleep apnea,treatment...s of our,expanding patient population," said Rober...
...ation Laboratory,(IL) today announced that its thr...lio with HealthTrust Purchasing Group, LP (HealthT...s been extended to all Consorta,Inc. members. Cons...organization, and HealthTrust finalized an agreeme...wner of HealthTrust, effective April 18,2007. The ...
Other Biology Technology:Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 3Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 4SleepQuest Launches Updated Web Site 2HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta 2
(Date:12/3/2009)... included in the design of the upcoming forest dea...risis, according to a scientist at the University ... Lewis argues that at least 50% of the carbon cred...EDD (Reducing Emissions from Deforestation and Deg...tly, and their property rights assured. , "There...
(Date:12/2/2009)...n exposed to secondhand cigarette smoke have an in...d, even if they never smoked. , Results of this...arkers & Prevention , a journal of the American As...l tobacco focus in the December issue. , This y...gnosed with lung cancer; more than 159,000 will di...
(Date:12/2/2009)...-American adolescents exposed to cigarette smoking...abit themselves, and this may be part of the accul...n, according to new study findings. , "Our study...ates and highlights the global implementation of t...on Tobacco Control, which includes guidelines for ...
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Healthcare Trust of America Inc Executes Agreement to Acquire a 108 500 SF Medical Office Building Located in Spartanburg South Carolina 61272 1Healthcare Trust of America Inc Executes Agreement to Acquire a 108 500 SF Medical Office Building Located in Spartanburg South Carolina 61272 2Bioniche Pharma Acquires Duraclon 28R 29 28clonidine hydrochloride injection 29 and Methadone Hydrochloride Injection USP 61269 1Bioniche Pharma Acquires Duraclon 28R 29 28clonidine hydrochloride injection 29 and Methadone Hydrochloride Injection USP 61269 2Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 1Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 2Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 3Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 4Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 5
...April 14, 2009 A new study finds that it will tak...d through the use of biofuels to compensate for th...shed on forestlands. If the original habitat was p...ears. The study appears in Conservation Biology ....or biofuel, has replaced soybean as the world,s mo...
...Extensive death of nerve cells leads to severe dem...now, it has only been possible to investigate the ... and by using complicated methods. Researchers at ... Ludwig-Maximilians-Universitaet (LMU) Muenchen, h...ssfully observed this demise of nerve cells by lif...
... Byproducts from the electronics, fuel, chemical a...c heavy metals like cadmium and lead can seep into...the soil, these dangerous materials can render par...vironmental, health and financial reasons, new sol...ls from America,s soil. , Now, an innovative Tel ...
Other Biology News:Biofuels could hasten climate change 2Alzheimer cell death in Zebrafish: Demise of neurons observed live for the first time 2A dirty job but ... 2
Blot module from GE Healthcare, formerly Amersham Biosciences
Rat Anti-Human CD66 acd Monoclonal Antibody, Unconjugated, Clone YTH71.3 from GeneTex
LB Broth Base powder (Lennox L Broth Base) from Invitrogen
Anti-Mouse IgGAM Polyclonal Antibody, Horseradish Peroxidase Conjugated from Invitrogen
Biology Products: